Drug Design is Not Gravity Filtration

Billions of research cost, years of development time, and lab automation do not guarantee outputs with value.

Inflexible Service Reflects Technological Immaturity

Suppose you are planning a trip abroad.

Do you accept a mobile service that disable all options except traditional roaming— despite your travel duration?

From Stagnation to Momentum

Outdated AI service models rely on rigid norms like royalty-based collaborations, target disclosure, and joint IP ownership.

Yet no assets from those pipelines have passed Phase 2.

We provide strategic revision of service frameworks to enable meaningful progress of your pipeline development.

AI Solutions

Top-tier Artificial Intelligence for 500x Productive Drug Design

Bioactivity Prediction

The wish for elegantly obtaining the best potency by a small number of design does not work in reality

Trial Efficacy Prediction

Enable confident pre-trial assessment of pipeline value for in-licensing decisions

Pediatric ADR Prediction

Reliable AI engine that safeguards young patients

More to Explore

Rewriting the Rules of Pediatric Safety

The future of pediatric care isn’t coming — it’s already here. We’re introducing Synoptic Intelligence to break the bottleneck in EHR‑based AI and safeguard children from harmful, unintended consequences of medical treatment.

Health and Economic Challenge of Adverse Drug Reactions in Children

The challenge and proactive solutions at a glance

Synoptic AI Engine Excels in Medical Record Interpretation

Synoptic Intelligence Resolves Discrepancy in Clinical Statistics and Outperforms 20x Larger Language Model in EHR Interpretation

3 Takeaways from Our Media Coverage

How our deep learning outperforms prominent models in bioactivity prediction and empowers practical, scalable solutions in real world

True Acceleration Saves Much More than You May Have Imagined

A tenfold reduction of the time for lead optimization saves the development expenses by 15 folds. More savings can be expected when it comes in synergy with the reduction of research cost.